{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:44:19Z","timestamp":1786977859113,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1704,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Cystic fibrosis liver disease (CFLD), which results from progressive hepatobiliary fibrosis, is an important cause of morbidity and mortality, but it is difficult to identify before portal hypertension (PHT) ensues. Clinical signs, serum alanine aminotransferase (ALT) levels, and ultrasound (US) are widely applied, but their value in predicting the presence of cirrhosis, the development of PHT, or adverse outcomes is undetermined. The potential gold standard, liver biopsy, is not standard practice and, notwithstanding sampling error considerations, has not been systematically evaluated. Forty patients with cystic fibrosis (median age = 10.6 years) with abnormal clinical, biochemical, and US findings were subjected to dual-pass percutaneous liver biopsy. Clinical outcomes were recorded over 12 years of follow-up (median = 9.5 years for survivors). Logistic regression and receiver operating characteristic analyses were applied to predict hepatic fibrosis (which was assessed by fibrosis staging and quantitative immunohistochemistry) and the occurrence of PHT. PHT occurred in 17 of 40 patients (42%), including 6 of 7 (17%) who died during follow-up. Clinical examination, serum ALT levels, and US findings failed to predict either the presence of liver fibrosis or the development of PHT. Fibrosis staging on liver biopsy, where the accuracy was improved by dual passes (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>= 0.002, nonconcordance = 38%), predicted the development of PHT (<\/jats:bold>\n                      <jats:bold>P<\/jats:bold>\n                      <jats:bold>&lt; 0.001), which occurred more frequently and at a younger age in those with severe fibrosis.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Clinical modalities currently employed to evaluate suspected CFLD help to identify a cohort of children at risk for liver disease and adverse outcomes but do not predict an individual's risk of liver fibrosis or PHT development. Liver fibrosis on biopsy predicts the development of clinically significant liver disease. Dual passes help to address sampling concerns. Liver biopsy has a relevant role in the management of patients with suspected CFLD and deserves more widespread application. (Hepatology 2011)<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.24014","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T10:18:48Z","timestamp":1285841928000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":106,"title":["Importance of hepatic fibrosis in cystic fibrosis and the predictive value of liver biopsy"],"prefix":"10.1097","volume":"53","author":[{"given":"Peter J.","family":"Lewindon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross W.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ristan M.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara N.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Frawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant A.","family":"Ramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 1","key":"R1-21-20250207","first-page":"S1S13","article-title":"Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group.","volume":"28","author":"Sokol","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R2-21-20250207","doi-asserted-by":"crossref","first-page":"11511158","DOI":"10.1002\/hep.510300527","article-title":"Natural history of liver disease in cystic fibrosis.","volume":"30","author":"Lindblad","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R4-21-20250207","doi-asserted-by":"crossref","first-page":"13741382","DOI":"10.1002\/hep.1840360613","article-title":"Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome.","volume":"36","author":"Colombo","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R5-21-20250207","doi-asserted-by":"crossref","first-page":"365370","DOI":"10.1053\/crad.2001.0861","article-title":"Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9year review.","volume":"57","author":"Williams","year":"2002","journal-title":"Clin Radiol"},{"key":"R6-21-20250207","doi-asserted-by":"crossref","first-page":"343350","DOI":"10.1067\/S0022-3476(03)00329-9","article-title":"Surveillance for cystic fibrosisassociated hepatobiliary disease: early ultrasound changes and predisposing factors.","volume":"143","author":"Lenaerts","year":"2003","journal-title":"J Pediatr"},{"issue":"Suppl 45","key":"R7-21-20250207","first-page":"1727","article-title":"The role of abdominal ultrasound in the diagnosis, staging and management of cystic fibrosis liver disease.","volume":"98","author":"Stewart","year":"2005","journal-title":"J R Soc Med"},{"key":"R8-21-20250207","first-page":"215221","article-title":"Comparison of ultrasound and biopsy findings in children with cystic fibrosis related liver disease.","volume":"7","author":"MuellerAbt","year":"2008","journal-title":"J Cyst Fibros"},{"key":"R9-21-20250207","first-page":"3236","article-title":"Can the histologic changes of cystic fibrosisassociated hepatobiliary disease be predicted by clinical criteria?","volume":"25","author":"Potter","year":"1997","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R10-21-20250207","doi-asserted-by":"crossref","first-page":"166174","DOI":"10.1002\/hep.510270126","article-title":"A twoyear prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosisassociated liver disease.","volume":"27","author":"Lindblad","year":"1998","journal-title":"HEPATOLOGY"},{"key":"R11-21-20250207","doi-asserted-by":"crossref","first-page":"334340","DOI":"10.1053\/jhep.2000.9111","article-title":"Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis.","volume":"32","author":"Kinnman","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R12-21-20250207","doi-asserted-by":"crossref","first-page":"16731682","DOI":"10.1002\/hep.20238","article-title":"Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.","volume":"39","author":"Smith","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R13-21-20250207","doi-asserted-by":"crossref","first-page":"533544","DOI":"10.1002\/hep.22637","article-title":"Fibrogenesis in pediatric cholestatic liver disease: role of taurocholate and hepatocytederived monocyte chemotaxis protein1 in hepatic stellate cell recruitment.","volume":"49","author":"Ramm","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R14-21-20250207","doi-asserted-by":"crossref","first-page":"17051715","DOI":"10.1016\/S0002-9440(10)61117-0","article-title":"The role of hepatic stellate cells and transforming growth factorbeta(1) in cystic fibrosis liver disease.","volume":"160","author":"Lewindon","year":"2002","journal-title":"Am J Pathol"},{"key":"R15-21-20250207","doi-asserted-by":"crossref","first-page":"576583","DOI":"10.1016\/j.jhep.2004.06.032","article-title":"Serum markers of hepatic fibrogenesis in cystic fibrosis liver disease.","volume":"41","author":"Pereira","year":"2004","journal-title":"J Hepatol"},{"key":"R16-21-20250207","first-page":"603605","article-title":"Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis?","volume":"27","author":"Leonardi","year":"1998","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R17-21-20250207","doi-asserted-by":"crossref","first-page":"10761083","DOI":"10.1001\/jama.2009.1295","article-title":"Genetic modifiers of liver disease in cystic fibrosis.","volume":"302","author":"Bartlett","year":"2009","journal-title":"JAMA"},{"key":"R18-21-20250207","doi-asserted-by":"crossref","first-page":"335347","DOI":"10.1016\/S1089-3261(02)00009-0","article-title":"Scoring of chronic hepatitis.","volume":"6","author":"Scheuer","year":"2002","journal-title":"Clin Liver Dis"},{"key":"R19-21-20250207","doi-asserted-by":"crossref","first-page":"13561358","DOI":"10.1016\/j.hep.2003.10.010","article-title":"Liver biopsy size matters in chronic hepatitis: bigger is better.","volume":"38","author":"Scheuer","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R20-21-20250207","first-page":"698701","article-title":"Prevalence of liver disease in cystic fibrosis.","volume":"66","author":"ScottJupp","year":"1991","journal-title":"Arch Dis Child"},{"key":"R21-21-20250207","doi-asserted-by":"crossref","first-page":"340346","DOI":"10.1056\/NEJM198802113180602","article-title":"Liver disease and commonbileduct stenosis in cystic fibrosis.","volume":"318","author":"Gaskin","year":"1988","journal-title":"N Engl J Med"},{"key":"R22-21-20250207","doi-asserted-by":"crossref","first-page":"332342","DOI":"10.1002\/hep.21972","article-title":"Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications.","volume":"47","author":"Talwalkar","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R23-21-20250207","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jhep.2008.10.016","article-title":"Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately?","volume":"50","author":"Bonekamp","year":"2009","journal-title":"J Hepatol"},{"key":"R24-21-20250207","doi-asserted-by":"crossref","first-page":"10831089","DOI":"10.1002\/hep.22748","article-title":"Factors of accuracy of transient elastography (FibroScan) for the diagnosis of liver fibrosis in chronic hepatitis C.","volume":"49","author":"Lucidarme","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R25-21-20250207","doi-asserted-by":"crossref","first-page":"252257","DOI":"10.1016\/j.jcf.2007.10.004","article-title":"A single centre experience of liver disease in adults with cystic fibrosis 19952006.","volume":"7","author":"Nash","year":"2008","journal-title":"J Cyst Fibros"},{"key":"R26-21-20250207","doi-asserted-by":"crossref","first-page":"14021408","DOI":"10.1111\/j.1478-3231.2007.01570.x","article-title":"The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid.","volume":"27","author":"Desmond","year":"2007","journal-title":"Liver Int"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24014","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201101000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:36:47Z","timestamp":1738928207000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201101000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24014","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}